Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which bring health education and free screenings for many cancer types to South Florida communities in need, are for the first time offering prostate-specific antigen (PSA) screening for prostate cancer.

Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.

Genomic Testing Can Identify African American Prostate Cancer Patients Who Have High-Risk Disease

Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer. The study results were published in the Journal of the National Cancer Institute.

MD Anderson Research Highlights for July 27, 2022

Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.

Moffitt Study Shows Adaptive Therapy Improves Outcomes, Reduces Care Costs for Prostate Cancer Patients

Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.

The Lancet Publishes Sylvester-Led Study Defining New Standard of Care for Prostate Cancer Recurrence After Prostatectomy

Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…

Moffitt Researchers Contribute to Discovery of Mechanism Leading to Drug Resistance in Prostate Cancer

In a new article published in Science Translational Medicine, Moffitt Cancer Center researchers reveal a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identify a potential treatment approach that could overcome this resistance.

Radiation Therapy as Effective as Surgery for Prostate Cancer

Radiation is an effective treatment for prostate cancer. Ronald D. Ennis, MD,Professor and Vice Chair of Network Integration and Quality, Department of Radiation Oncology at Rutgers Cancer Institute, along with Lara Hathout, MD, FRCPC, radiation oncologist and director of Brachytherapy at Rutgers Cancer Institute and associate Professor of radiation oncology at Rutgers Robert Wood Johnson Medical School share more

Henry Ford Health is First in the World to Offer Latest Advancement in MR-Guided Radiation Therapy

Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.

New Combined Therapy Helps Extend Lives of Men With Prostate Cancer

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.

Researchers uncover how tumors circumvent prostate cancer therapy, identify promising treatment strategy

A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment. Findings were published in Proceedings of the National Academy of Sciences (PNAS). Antiandrogen strategies remain the backbone for advanced prostate…

TipSheet: Research Highlights Potential Benefits of Vibrators on Women’s Pelvic Health

Cedars-Sinai urology experts will present their latest advances in urologic medicine at the annual scientific meeting of the American Urological Association (AUA) in New Orleans May 13-16, 2022. Among over 2,200 abstracts, one by Alexandra Dubinskaya, MD, a female pelvic medicine and reconstructive surgery (FPMRS) specialist—Is It Time for FPMRS to Prescribe Vibrators?—was selected to be included in the 117th AUA press session on May 13, 2022, at 9 a.m. CT.

Henry Ford Health First in Michigan to Offer Robotic High-Intensity Focused Ultrasound for Prostate Cancer

Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.

April Research Highlights

This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.

Yale Cancer Center Study Shows Rates of PSA Testing for Prostate Cancer Increased After Revised National Guidelines

In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.

Studies Find B7-H3 Protein a Novel, Promising Target for Prostate Cancer Treatments

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies were presented recently at the European Society for Medical Oncology (ESMO) 2021 Conference.

Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery

Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.

New Noninvasive Tests for Colon and Prostate Cancer Presented at the 2021 AACC Annual Scientific Meeting

Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment

For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Advancements in Prostate Cancer Treatments are Providing Better Outcomes for Men

Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.

Mount Sinai researchers develop novel therapy that could be effective in many cancers

New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…

Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center

Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…